2025 ASM Satellite - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

View content and claim credit on the Voxmedia site!

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

Program Overview

Around 50% of patients experience heart failure (HF) symptoms/signs in the presence of a preserved left ventricular ejection fraction, and half of these patients have increased left ventricular wall thickness. Transthyretin amyloid cardiomyopathy (ATTR-CM), a restrictive cardiomyopathy resulting from the deposition of amyloid fibrils in the interstitial space of the heart muscle, commonly fits these characteristics. ATTR-CM has been increasingly recognized as a much more frequent cause of HF than previously thought; it is a progressive and fatal condition if not diagnosed promptly. Multiple disease-modifying therapies for ATTR-CM are now available, and other treatments are under investigation. However, the condition remains misdiagnosed and underdiagnosed since awareness of the disease among clinicians and in the community is less than optimal. In this symposium, Chair Dr. Mathew Maurer, and faculty members Dr. Noel Dasgupta, Dr. Omar Abou Ezzeddine, and Dr. Frederick Ruberg, will explain best practices for screening and diagnosing ATTR-CM in patients with concomitant HF, describe the treatment landscape, and, through case presentation, discuss practical considerations in management.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

Agenda

Introduction
Mathew Maurer, MD (Chair)

ATTR-CM: Red Flags and Keys to Diagnosis
Frederick Ruberg, MD

Treating ATTR-CM in Patients with HF: The Changing Landscape
Mathew Maurer, MD

Case Presentation with Panel Discussion:

Managing ATTR-CM and HF in Clinical
Practice: From Red Flags to Monitoring Disease Progression

Case Presenter: Omar Abou Ezzeddine, MD, MS

Panelists: Noel Dasgupta, MD; Mathew Maurer, MD; Frederick Ruberg, MD

Question and Answer

Summary

Cost:

FREE

Credit:

"[HIDE_MESSAGE]"

Create Account